Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

Choose the language:

  Homepage
Continue on the current website:  

 

IB Delta T1 Maps

Performs post-processing of MR T1-weighted images of the brain and simplifies post-processing tasks.

Inquire Now

Imaging
  • T1
  • contrast enhancement
  • regions of interest
  • ROI

IB Delta T1 Maps allows the user to perform a range of common tasks such as co-registering datasets, creating subtraction maps, and exporting class maps based on user-determined image thresholds. IB's Delta T1 (dT1) maps have demonstrated the ability to aid in the detection of subtle contrast enhancement on post-contrast T1-weighted images. Eliminates confounding factors such as post-surgical blood products, fat and proteinaceous material, and can generate quantitative dT1 maps. Makes the delineation of contrast enhancing regions objective, faster, and consistent and comparison to previous time points easier and faster.

 

Output includes an anatomic image showing the areas of true contrast enhancement.

IB Delta T1 Sensitivity

IB Delta T1 may provide greater sensitivity for stratifying subpopulations over adjudicated 2D manual delineation of enhancing tumor reads.1

1Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AJNR Am J Neuroradiol. 2019 Jul;40(7):1132-1139. doi: 10.3174/ajnr.A6110. Epub 2019 Jun 27. PMID: 31248863; PMCID: PMC6620020.

IB Delta T1 Sensitivity

Can predict early progression comparable with standard 2D manual methods but has the potential for substantial time and cost savings for clinical trials.1

1Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AJNR Am J Neuroradiol. 2019 Jul;40(7):1132-1139. doi: 10.3174/ajnr.A6110. Epub 2019 Jun 27. PMID: 31248863; PMCID: PMC6620020.

 

    Use existing neuro imaging protocols

    Use existing neuro imaging protocols

    Delta T1 maps apply to any neuro exam consisting of pre- and post-contrast T1w images

    References

    References

    1. IB Clinic 2.0 release 21.12 User Manual
    2. Prah et al, Repeatability of Standardized and Normalized Relative CBV, AJNR Am J Neuroradiology, 2015
    3. Hu, et al, Impact of Software Modeling on the Accuracy of Perfusion MRI, AJNR Am J Neuroradiology, 2015
    4. Schmainda et al, Quantitative Delta T1 (dT1), AJNR Am J Neuroradiology, 2019
    5. Schmainda, Diffusion­ weighted MRI as a biomarker for treatment response in glioma, CNS Oncol, 2012

    What Customers Are Saying

    The T1 with contrast is hard to interpret, but I think the Delta T1 says it all.

    Dr Jennifer Connelly
    Associate Professor of Neurology and Co-Director of the Neuro-oncology Program at Froedtert and the Medical College of Wisconsin.

    May not reflect a typical user experience; actual results may vary.

    What Customers Are Saying

    When new areas of enhancement are identified, our surgeons and neuro-oncologists want to see IB's Delta T1 maps and standardized rCBV on our patients to guide therpeutic and surgical management. The additional information added by IB's maps to conventional imaging is instrumental in patient management.

    Dr Johr Karis,
    MO Neuroradiologist at Southwest Neuro-lmaging lid.

    May not reflect a typical user experience; actual results may vary.

    Request a demo

    See Ahead for Yourself

    Inquire now
    LinkedIn LinkedIn

    © 2022, 2023 Bayer

    The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

    BAYER, the Bayer Cross, Radimetrics and Calantic are trademarks owned by Bayer and/or registered in the U.S. Other trademarks and company names mentioned herein are properties of their respective owners.

    This is intended to provide information for healthcare professionals and other relevant decision makers in the US. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

     

    Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information.

     

    You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

    Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

     

    Bayer U.S. | Digital Solutions, 100 Bayer Blvd., Whippany, NJ 07981-0915

     

    Last Updated: September 2023

    © 2022, 2023, 2024, 2025 Bayer

    The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

    BAYER, the Bayer Cross, Radimetrics and Calantic are trademarks owned by Bayer and/or registered in the U.S. Other trademarks and company names mentioned herein are properties of their respective owners.

    This is intended to provide information for healthcare professionals and other relevant decision makers in the US. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

     

    Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information.

     

    You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

    Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

     

    Bayer U.S. | Digital Solutions, 100 Bayer Blvd., Whippany, NJ 07981-0915

     

    Last Updated: March 2025

    Bayer Logo
    • United States